INTRODUCTION: Increasing evidence has shown benefits with the use of furosemide for patients with hypertensive disorders of pregnancy (HDP) in the postpartum period. We compared outcomes of patients diagnosed with HDP who received a standard protocol of postpartum furosemide versus those who had routine postpartum care. METHODS: In February 2022, a standardized, multidisciplinary postpartum furosemide protocol was instituted for patients with HDP. Exclusion criteria included hypokalemia, receiving concomitant diuretics, creatinine greater than 1.2 mg/dL, stenotic valvular cardiac disease, hemodynamic instability, or body mass index less than 18. We compared patients prior to routine furosemide use (June 2020 to January 2022) to patients treated under the protocol (February 2022 to July 2022). Outcomes included hypertension defined as systolic blood pressure (BP) greater than 139 or diastolic BP greater than 89 at 6–14 days postpartum, need for additional antihypertensive medications, readmissions, and show-rate for postpartum outpatient visits. Nonparametric tests were used to compare outcomes between the groups. Study was exempt from the IRB. RESULTS: A total of 129 patients were identified who met inclusion criteria. 80 patients met criteria prior to protocol implementation, and 49 patients met criteria after implementation. The furosemide group had a significant reduction in hypertension at 6–14 days postpartum (22.86% versus 55.26%, odds ratio 0.24, 95% CI 0.09–0.66) compared to the group who did not receive furosemide. No adverse events were noted in the furosemide group. CONCLUSION: Administration of a short course of furosemide to postpartum patients with HDP appears to improve BP recovery in the days immediately after delivery. Further studies examining hemodynamic changes after furosemide use are needed.